SCHEMBL3538797

SCHEMBL3538797

Cn1c(-c2n[nH]c3ccc(Oc4cccnc4)cc23)nc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PPARG P37231 1/20 0.40
LMNA P02545 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
METAP2 P50579 1/20 0.39
FGFR1 P11362 3/20 0.38
TTK P33981 1/20 0.38
LRRK2 Q5S007 2/20 0.38
PDE10A Q9Y233 2/20 0.38
IDO1 P14902 1/20 0.38
CHEK2 O96017 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
PAX8 Q06710 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
AKT1 P31749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538710 0.91 CHEK2 (0.45) MEN1KMT2ALMNAMETAP2FGFR1
SCHEMBL3536975 0.88 PPARG (0.41) MAP2K4PPARGLMNATDP1METAP2
SCHEMBL3537783 0.88 MEN1 (0.41) MAP2K4MEN1KMT2ALMNAFGFR1
SCHEMBL3535791 0.87 TP53 (0.47) MEN1KMT2ATTKLRRK2KDM4E
SCHEMBL3532370 0.86 HTT (0.47) MEN1KMT2ALMNATTKKDM4E
SCHEMBL3535697 0.86 HTR2B (0.41) MAP2K4METAP2FGFR1CYP11B1CYP11B2
SCHEMBL3536897 0.86 KDM4E (0.43) MEN1KMT2APPARGLMNAFGFR1
SCHEMBL3538380 0.85 SCN9A (0.45) MEN1KMT2ALMNAFGFR1TTK
SCHEMBL3541245 0.85 TTK (0.40) MEN1KMT2ALMNAMETAP2TTK
SCHEMBL3536646 0.82 DRD1 (0.42) MEN1KMT2APPARGLMNAMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK MAP2K4 1134/4885MEN1 1771/4885KMT2A 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.